All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, Sobi and Takeda and supported through independent educational grants from Bristol Myers Squibb, Blueprint Medicines, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View MPN content recommended for you
Phase IIIb JUMP trial: Post hoc analysis of ruxolitinib ± ESA/danazol in patients with MF and anemia
Results from a post hoc analysis of the phase IIIb JUMP (NCT01493414) trial evaluating ruxolitinib ± anemia-supporting therapies in patients with myelofibrosis (MF) and anemia (hemoglobin [Hb] <12.0 g/dL) were published in Hematology by Vachhani et al. The analysis set included patients who initiated erythropoiesis-stimulating agent (ESA) or danazol <3 months post-enrollment and maintained ESA/danazol for ≥3 months (Hb <12.0 g/dL, n = 101; Hb <10.0 g/dL, n = 52); patients who had Hb <12.0 g/dL but did not initiate anemia-supporting medications within 3 months acted as an unmatched comparator (n = 1,242). Patients were evaluated for spleen length response (SLR), defined as ≥50% reduction from baseline in palpable spleen length, at Weeks 12 and 24, and for Functional Assessment of Cancer Therapy–Lymphoma (FACT-Lym) total score (TS) symptom response, defined as an ≥6.5-point increase from baseline, at Week 24.
Key data: Mean total daily ruxolitinib dose was maintained at near or above 25 mg throughout the study in all subgroups. At Week 12, 41.6% of patients in the analysis set demonstrated an SLR, including 42.3% of patients in the Hb <10.0 g/dL subset, compared with 35.0% of patients who did not initiate anemia-supporting therapies. At Week 24, 36.6% of patients in the analysis set had an SLR, including 34.6% of patients in the Hb < 10.0g/dL subset, compared with 28.4% of patients who did not initiate anemia-supporting therapies and 31.5% of patients in the total JUMP population. At Week 24, a FACT-Lym TS symptom response was demonstrated by 25.7% of patients in the analysis set, including 23.1% of patients in the Hb <10.0 g/dL subset; similar rates were observed in patients who did not initiate anemia-supporting therapies (26.5%) and the overall JUMP population (26.9%). Hb levels dropped through Week 4 but recovered to baseline by Week 48.
Key learning: In this post hoc analysis of the JUMP trial, the addition of anemia-supporting therapies to ruxolitinib preserved spleen and symptom response rates in patients with MF and anemia.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
Among patients with myelofibrosis and isolated anemia at presentation, with no indication for treatment with a JAK inhibitor, how often do you use anemia-directed treatments (EMAs, ESAs, danazol, etc.) as monotherapy?
